noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Monte Rosa Therapeutics Inc.

AACR 2026 – Selective targeting of CCNE1 using molecular glue degraders[...]
Suhas Subramanyam

Subramanyam and Luna Introduce Bipartisan Bill to Reform Congressional[...]
Gabe Vasquez

Rep. Vasquez’s Downwinder Commemoration Act Advances to House Floor[...]

Healthcare

Revolution Medicines Inc.

04/21/2026 | Press release | Distributed by Public on 04/21/2026 15:34

Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting

You don't have permission to access "http://ir.revmed.com/news-releases/news-release-details/revolution-medicines-present-preclinical-data-innovative-mutant" on this server.

Reference #18.91721102.1776807250.3d2fd080

https://errors.edgesuite.net/18.91721102.1776807250.3d2fd080

Revolution Medicines Inc. published this content on April 21, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 21, 2026 at 21:34 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]